Laurence Albiges, MD, PhD, of Gustave Roussy, provides an overview of the CheckMate 67T trial, a phase 3 study evaluating the safety and efficacy of subcutaneous administration of nivolumab compared to intravenous administration in patients with renal cell carcinoma. Dr. Albiges highlights the study’s key findings, including its success in meeting co-primary endpoints of pharmacokinetic non-inferiority and comparable clinical activity.
Subcutaneous Nivolumab for RCC: CheckMate 67T Practice-Changing Results
By Laurence Albiges, MD, PhD - Last Updated: January 2, 2025Related Posts
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
The combination therapy provided similar survival rates and toxicity in an older patient population.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
First-line IO + IO therapy is linked to higher costs during the first three months of treatment.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.